A pooled analysis of 23 phase 1-2 trials suggests neoadjuvant chemoimmunotherapy for resectable head and neck squamous cell carcinoma produces markedly higher major to complete pathologic response rates (66%) compared with immunotherapy alone (6-18% with single- or dual-agent regimens) supporting a phase 3 evaluation. | Baratiz, JAMA Otolaryngol Head Neck Surg 2026
